Table 4 Absolute changes in GLS, segmental strain and estimated LVEF% after receiving antiviral treatment in dual and triple DAA regimen populations

EF

0.71 ± 1.04

0.69 ± 0.87

0.176

GLS

1.07 ± 0.32

1.02 ± 0.15

0.257

Basal anterior

1.12 ± 8.06

1.02 ± 8.06

0.952

Basal anteroseptal

1.06 ± 3.32

1.26 ± 3.32

0.881

Basal anterolateral

1.3 ± 6.04

1.28 ± 6.04

0.466

Basal inferior

1.39 ± 7.34

1.29 ± 7.34

0.681

Basal inferoseptal

1.22 ± 4.98

1.25 ± 4.98

0.245

Basal inferolateral

1.07 ± 5.81

1.17 ± 5.81

0.727

Mid anterior

1.29 ± 7.41

1.23 ± 7.41

0.483

Mid anteroseptal

1.17 ± 9.84

1.12 ± 9.84

0.858

Mid anterolateral

1.08 ± 3.86

1.18 ± 3.86

0.230

Mid inferior

1.15 ± 6.17

1.12 ± 6.17

0.733

Mid inferoseptal

1.18 ± 5.42

1.08 ± 5.42

0.996

Mid inferolateral

1.03 ± 6.14

1.01 ± 6.14

0.365

Apical anterior

1.17 ± 12.83

1.07 ± 12.83

0.365

Apical septal

0.71 ± 1.04

0.69 ± 0.87

0.176

Apical inferior

1.07 ± 0.32

1.02 ± 0.15

0.257

Apical lateral

1.12 ± 8.06

1.02 ± 8.06

0.952